In a recent ‘Viewpoint’ article, Dr. Fauci, Director of NIAID, mentioned that “industry has expanded the pipeline of new antibacterial drugs…with 14-agents currently in phase 3 clinical trials”. Regarding the number of drugs in late development, his statement may be correct Continue reading The Antibiotic Pipeline: How “New” is New
An interesting report has just been published showing that Naloxegol is beneficial in OIC [i]. Naloxegol is a µ opioid receptor (MOR) antagonist which – by virtue of pegylation – acts peripherally and not centrally. Hence, the analgesic effects of Continue reading Trial Pains Secondary to Placebo Effect?